Login/Register

QIAGEN-HSMD

Taiwan
Partnership wanted
Introduction
The QIAGEN Human Somatic Mutation Database (HSMD) is a database developed by QIAGEN for querying somatic mutation loci in tumor cells. This database contains information from over 419,000 clinical tumor cases and more than 1.5 million mutations. It integrates with the QIAGEN knowledge database to provide gene, mutation, and disease-related information, including mutation frequencies observed in clinical cases.

HSMD is updated weekly, allowing researchers to access and explore the latest information on somatic mutations in tumor cells, drugs, clinical trials, and more. It assists in investigating whether there is relevant clinical data associated with mutation loci, identifying therapeutic potential for these loci, and providing approved drugs and therapies for treatment strategies. Additionally, HSMD helps in rapidly identifying treatment targets and target patients for drug development directions.
Features / strengths
●Analysis report generation
●Drug and clinical therapy inquiry
●In-depth understanding of a specific tumor type in patients
●Ranking of gene or mutation grades
Specification in detail

Information
Introduction
The QIAGEN Human Somatic Mutation Database (HSMD) is a database developed by QIAGEN for querying somatic mutation loci in tumor cells. This database contains information from over 419,000 clinical tumor cases and more than 1.5 million mutations. It integrates with the QIAGEN knowledge database to provide gene, mutation, and disease-related information, including mutation frequencies observed in clinical cases.

HSMD is updated weekly, allowing researchers to access and explore the latest information on somatic mutations in tumor cells, drugs, clinical trials, and more. It assists in investigating whether there is relevant clinical data associated with mutation loci, identifying therapeutic potential for these loci, and providing approved drugs and therapies for treatment strategies. Additionally, HSMD helps in rapidly identifying treatment targets and target patients for drug development directions.
Features / strengths
●Analysis report generation
●Drug and clinical therapy inquiry
●In-depth understanding of a specific tumor type in patients
●Ranking of gene or mutation grades
Specification in detail

QIAGEN-HSMD

Taiwan
BIONET Corp. Other products
Recommended